ESR1 and breast carcinoma: In conclusion, the collective results shown here that PR isoforms, agonists and antagonists distinctly reprogram estrogen signaling, warrants additional research into appropriate combination therapies to treat ER+/PR+ breast cancers (Figure 5G).